Agios Pharmaceuticals (AGIO) Stock Analysis

What Agios Pharmaceuticals does

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Key metrics

ETFs linked to AGIO

Broad-market and Healthcare sector ETFs an investor holding Agios Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AGIO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Agios Pharmaceuticals?

Agios Pharmaceuticals trades under the ticker AGIO on NASDAQ.

Which exchange is AGIO listed on?

AGIO is listed on NASDAQ.

What sector does Agios Pharmaceuticals operate in?

Agios Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AGIO in a portfolio?

PortView shows AGIO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.